NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 38.2% in December

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 1,744,957 shares, an increase of 38.2% from the November 30th total of 1,262,366 shares. Based on an average trading volume of 495,030 shares, the days-to-cover ratio is currently 3.5 days. Approximately 7.3% of the shares of the stock are short sold. Approximately 7.3% of the shares of the stock are short sold. Based on an average trading volume of 495,030 shares, the days-to-cover ratio is currently 3.5 days.

NRx Pharmaceuticals Stock Up 1.2%

Shares of NRx Pharmaceuticals stock traded up $0.03 during trading on Tuesday, reaching $2.63. 267,372 shares of the company were exchanged, compared to its average volume of 493,333. The business has a 50-day moving average price of $2.50 and a 200-day moving average price of $2.81. The firm has a market capitalization of $77.85 million, a price-to-earnings ratio of -1.12 and a beta of 1.91. NRx Pharmaceuticals has a twelve month low of $1.47 and a twelve month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $6.83 million. On average, equities research analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Anson Funds Management LP increased its stake in NRx Pharmaceuticals by 26.2% in the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after purchasing an additional 420,129 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares during the period. Vanguard Group Inc. increased its position in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. AdvisorShares Investments LLC raised its stake in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares during the period. Finally, One Wealth Management Investment & Advisory Services LLC raised its stake in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NRXP shares. Zacks Research upgraded shares of NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. D. Boral Capital reissued a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, December 2nd. Ascendiant Capital Markets boosted their target price on NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, December 16th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.